TriangleNCT00004227 · CITED IN SOURCE DOCUMENTS
Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- TERMINATED
- Registry last update
- 2014-02-06
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- DISEASE CHARACTERISTICS: * Histologically proven advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx * Stage III OR * Stage IV without distant metastases * Measurable disease * Tumor tissue available for immunohistochemical assay of epidermal growth factor receptor expression PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 60-100% Life expectancy: * At least 1 year Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT and SGPT no greater than 2 times upper limit of normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 50 mL/min * Calcium normal Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Medically able to withstand a course of definitive radiotherapy * No medical or psychologic condition that would preclude informed consent or compliance * No other malignancy within the past 3 years except basal cell skin cancer or preinvasive carcinoma of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior cetuximab or other murine monoclonal antibody Chemotherapy: * At least 3 years since prior systemic chemotherapy * No concurrent chemotherapy Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy to head and neck * No other concurrent radiotherapy Surgery: * No prior surgery for indicator lesion except biopsy * Study radiotherapy must not be a part of a postoperative regimen after primary surgical resection
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients undergo radiotherapy beginning on day 1. Patients are assigned to 1 of 3 radiotherapy groups: * Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks. * Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks. * Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks.
- intervention Names
- Procedure: conventional surgery
- Radiation: radiation therapy
- label
- Arm I
- type
- PLACEBO_COMPARATOR
- description
- Patients receive a test dose of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4 anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30 minutes after completion of test dose. Patients receive maintenance cetuximab IV over 1 hour on day 8. Maintenance cetuximab repeats every week for 7 courses. Beginning on day 8, patients undergo radiotherapy as in arm I concurrently with maintenance cetuximab. There must be an hour interval between the completion of cetuximab infusion and the start of any radiotherapy. Radiotherapy groups remain the same as in Arm I: * Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks. * Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks. * Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks.
- intervention Names
- Biological: cetuximab
- Procedure: conventional surgery
- Radiation: radiation therapy
- label
- Arm II
- type
- ACTIVE_COMPARATOR
- interventions
- arm Group Labels
- Arm II
- name
- cetuximab
- type
- BIOLOGICAL
- arm Group Labels
- Arm I
- Arm II
- name
- conventional surgery
- type
- PROCEDURE
- arm Group Labels
- Arm I
- Arm II
- name
- radiation therapy
- type
- RADIATION
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 32
- type
- ACTUAL
Registered outcome plans (not posted results)
Full study description
- brief Summary
- RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.
- detailed Description
- OBJECTIVES: * Compare the rate of locoregional disease control maintained for 1 year in patients with advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx treated with radiotherapy with or without concurrent cetuximab. * Compare the response rates, progression-free survival and overall survival rates, and quality of life in patients treated with these regimens. * Compare acute and late toxicity of these regimens in these patients. * Determine tumor epidermal growth factor receptor levels in patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified by Karnofsky performance status (60-80% vs 90-100%), nodal stage (N0 vs N+), tumor stage (T1-3 vs T4), and radiotherapy schedule (concurrent boost vs once daily vs twice daily). Patients are randomized to 1 of 2 treatment arms: * Arm I: Patients undergo radiotherapy beginning on day 1. Patients are assigned to 1 of 3 radiotherapy groups: * Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks. * Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks. * Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks. * Arm II: Patients receive a test dose of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4 anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30 minutes after completion of test dose. Patients receive maintenance cetuximab IV over 1 hour on day 8. Maintenance cetuximab repeats every week for 7 courses. Beginning on day 8, patients undergo radiotherapy as in arm I concurrently with maintenance cetuximab. There must be an hour interval between the completion of cetuximab infusion and the start of any radiotherapy. Patients with more than N1 neck disease at initial presentation undergo neck dissection 4-8 weeks after the completion of radiotherapy. Quality of life is assessed before initiation of study therapy, at 8 weeks, and then every 4 months for 1 year. Patients are followed at 8 weeks, every 4 months for 2 years, and then every 6 months for 3 years. PROJECTED ACCRUAL: Approximately 416 patients (208 per arm) will be accrued for this study within approximately 5 years.
Source references
- references
- citation
- Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10.
- pmid
- 19897418
- type
- RESULT
- citation
- Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78. doi: 10.1056/NEJMoa053422.
- pmid
- 16467544
- type
- RESULT
- citation
- Bonner JA, Harari PM, Giralt J, et al.: The relationship of cetuximab-induced rash and survival in patients with head and neck cancer treated with radiotherapy and cetuximab. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-120, S73, 2005.
- type
- RESULT
- citation
- Bonner JA, Girald J, Harari PM, et al.: Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-31, S147-8, 2004. Available online. Last accessed February 3, 2005.
- type
- RESULT
- citation
- Bonner J, Giralt J, Harari P, Spencer S, Schulten J, Hossain A, Chang SC, Chin S, Baselga J. Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):842-9. doi: 10.1001/jamaoto.2016.1228.
- pmid
- 27389475
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-5d6b85cd057fcaa4ecd4
- requested nct id
- NCT00004227
- primary nct id
- NCT00004227
- source kind
- fda_spl_label
- source record id
- 1cd448bd-5230-450c-ad4c-359e6d54cd2b
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- 96966010fb75f3b9135b1b383d018c9acffa547a395bc7a48645779fc4b1332e
- payload
- application numbers
- BLA125084
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-5d6b85cd057fcaa4ecd4
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004227
- occurrences
- context exact
- 14 CLINICAL STUDIES 14.1 Squamous Cell Carcinoma of the Head and Neck (SCCHN) In Combination with Radiation Therapy BONNER (NCT00004227) was a randomized, multicenter, controlled trial of 424 patients with locally or regionally advanced SCCHN. Patients with Stage III/IV SCCHN of the oropharynx,
- end
- 135
- exact text
- NCT00004227
- start
- 124
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/98/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 1cd448bd-5230-450c-ad4c-359e6d54cd2b
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- fa4da85c619cd62b341fcaec9e211f4ac23f572d1a5e3d4f6003330dea2232b2
- spl effective time
- 20260416
- spl set id
- 8bc6397e-4bd8-4d37-a007-a327e4da34d9
Preserved source evidence · Not medical advice